BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $54 from $55 and keeps a Buy rating on the shares. The firm sees Agios’ ...

OKYO Pharma (OKYO) announces that its lead asset, OK-101, has been officially assigned the United States Adopted Name, USAN, “urcosimod”. Gary ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with ...

In this article, we are going to take a look at where Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care ...